Ascendis Pharma (NasdaqGS:ASND) has drawn investor attention after recent share price swings, with the stock down about 4% over the past month but slightly higher over the past week.

At a latest share price of $238.01, Ascendis Pharma has seen its 7 day share price return of 2.97% partially offset a 1 month share price decline of 3.66%, while the year to date share price return is down 3%. This suggests that momentum has been choppy rather than firmly building or fading as investors reassess both growth prospects and risk around its endocrinology and oncology pipeline.

If Ascendis Pharma has you looking beyond a single stock, this is a good moment to scan the wider healthcare opportunity set using our screener of 38 healthcare AI stocks

So with Ascendis Pharma trading at $238.01 and showing mixed recent returns, is the current valuation still leaving a margin of safety for new investors, or has the market already priced in its future growth potential?

Most Popular Narrative: 30.4% Undervalued

Against Ascendis Pharma's last close of $238.01, the most widely followed narrative points to a fair value closer to the low $300s, implying a sizeable valuation gap based on long term growth and profitability assumptions.

Partnerships such as the collaboration with Novo Nordisk on once monthly TransCon semaglutide and ex U.S. partners like Teijin for endocrine products extend the TransCon model into larger disease areas and additional geographies. This can add new royalty or collaboration streams alongside product sales and support earnings as R&D productivity improves.

Want to see what kind of revenue ramp and margin profile would need to sit behind that outlook? The narrative hinges on steep top line growth, sharply higher profitability and a richer earnings multiple than the broader biotech sector. Curious which assumptions really move the fair value line for Ascendis Pharma?

Result: Fair Value of $342.08 (UNDERVALUED)

However, the bullish Ascendis Pharma narrative could be challenged if YORVIPATH uptake stalls, or if TransCon CNP timelines and approvals slip versus current expectations.

Next Steps

If the mixed sentiment around Ascendis Pharma leaves you undecided, take a closer look at the details, quickly weigh both sides, and shape your own view with 4 key rewards and 2 important warning signs

Looking for more Ascendis Pharma sized investment ideas?

If Ascendis Pharma has sharpened your focus on quality opportunities, do not stop here. The next set of ideas could be the ones you regret missing later.

• Spot potential value plays early by scanning 44 high quality undervalued stocks that may offer quality fundamentals at prices some investors overlook.
• Strengthen your downside protection by reviewing 69 resilient stocks with low risk scores that score well on resilience and balance sheet robustness.
• Get ahead of the crowd by checking the screener containing 18 high quality undiscovered gems that combine solid financials with lower market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.